Rainbow Childrens Medicare
Market cap ₹12,726 Cr
- P/E
- 43.68
- Day range
- ₹1,250.00 – ₹1,293.00
- 52-week range
- ₹1,084.00 – ₹1,610.00
- Volume
- 77,140
- Open
- ₹1,293.00
- Prev close
- ₹1,270.40
Latest results · Q2 FY27(consolidated)Revenue ₹548 Cr+23.2%Profit ₹84 Cr+10.9%Margin 15.3%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
RAINBOW in NSE indices and F&O
Research profile
Composite 54 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.3%
- Graham no.
- ₹328.98
- vs Graham
- -73.8%
- ROE ÷ P/B
- 2.4%
- 12-1 mom.
- -7.5%
- Return / vol
- -0.29
- Magic Formula
- #408
- Piotroski
- 3/6
- FCF yield
- 1.6%
- PEG
- 3.99
Appears in 7 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Rainbow Childrens MedicareRAINBOW | ₹12,726 Cr | 43.68 | 7.56 | 18.1% | 17.0% | 31.0% | 0.56 | +23.1% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 10d agoHeadlines about Rainbow Childrens Medicare from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 44.2
- Price / Book
- 7.44
- ROE (FY26)
- 18.1%
- ROCE (latest year)
- 17%
- Dividend yield
- 0.27%
Moving averages (NSE)
- 20-day
- ₹1,237.8
- Price above
- 50-day
- ₹1,308.01
- Price below
- 200-day
- ₹1,322.38
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 336 | 341 | 330 | 417 | 398 | 370 | 353 | 445 | 445 | 460 | 470 | 548 |
| Expenses | 218 | 236 | 236 | 270 | 264 | 255 | 249 | 296 | 298 | 315 | 335 | 378 |
| Operating Profit | 118 | 106 | 94 | 147 | 134 | 115 | 104 | 149 | 147 | 145 | 135 | 170 |
| OPM % | 35% | 31% | 28% | 35% | 34% | 31% | 29% | 33% | 33% | 31% | 29% | 31% |
| Other Income | 9 | 13 | 12 | 11 | 13 | 15 | 20 | 8 | 11 | 4 | 13 | 8 |
| Interest | 14 | 17 | 18 | 18 | 18 | 18 | 18 | 19 | 20 | 20 | 21 | 22 |
| Depreciation | 28 | 32 | 34 | 35 | 35 | 34 | 34 | 36 | 40 | 41 | 42 | 45 |
| Profit before tax | 85 | 69 | 53 | 105 | 94 | 77 | 71 | 102 | 98 | 87 | 84 | 112 |
| Tax % | 26% | 26% | 26% | 25% | 27% | 27% | 25% | 26% | 24% | 10% | 26% | 25% |
| Net Profit | 63 | 51 | 40 | 79 | 69 | 57 | 54 | 76 | 74 | 78 | 63 | 84 |
| EPS in Rs | ₹6.12 | ₹5.02 | ₹3.89 | ₹7.77 | ₹6.76 | ₹5.55 | ₹5.27 | ₹7.41 | ₹7.14 | ₹7.59 | ₹5.96 | ₹8.08 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-3 days since Mar 2021
+31 days since Mar 2021
-28 days since Mar 2021
+57 days since Mar 2021
+25 days since Mar 2021
Strengths, risks & growth
Rainbow Children's Medicare Limited operates a multi-specialty pediatric, obstetrics, and gynecology hospital chain in India. The company offers a wide range of services such as newborn and pediatric intensive care, pediatric multi-specialty services, pediatric quaternary care, obstetrics, and gynecology. [1] It is country’s largest pediatric hospital chain with 16 hospitals spread across 6 cities. [2]
Strengths
- Company's median sales growth is 22.8% of last 10 years
Risks
- Stock is trading at 7.57 times its book value
Compounded Sales Growth
- 10 Years
- +22%
- 5 Years
- +21%
- 3 Years
- +13%
- TTM
- +23%
Compounded Profit Growth
- 10 Years
- +31%
- 5 Years
- +46%
- 3 Years
- +7%
- TTM
- +16%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +6%
- 1 Year
- -2%
Return on Equity
- 10 Years
- +18%
- 5 Years
- +20%
- 3 Years
- +17%
- Last Year
- +17%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 49.84% | 49.84% | 49.84% | 49.83% | -0.01 pp |
| FII | 19.24% | 17.24% | 16.03% | 14.66% | -1.37 pp |
| DII | 19.49% | 21.12% | 22.56% | 23.28% | +0.72 pp |
| Public | 11.40% | 11.68% | 11.39% | 11.84% | +0.45 pp |
| Others | 0.04% | 0.12% | 0.18% | 0.40% | +0.22 pp |
Filed with NSE for Sept 2026: promoters 49.83%, public 49.77%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 18.91% (+0.35 pp)- Promoters50.0%
- Foreign institutions14.7%
- Mutual funds18.9%
- Insurance2.8%
- Other domestic institutions1.7%
- Retail5.5%
- Others6.3%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| ICICI Pru Large & Mid Cap Fund | 2.12% | 0.86% | -0.28 pp |
| Motilal Oswal Small Cap Fund | 1.52% | 2.35% | -0.35 pp |
| DSP Small Cap Fund | 1.46% | 0.92% | -0.23 pp |
| ICICI Pru Multi Asset Allocation Fund | 1.27% | 0.20% | -0.04 pp |
| Axis Small Cap Fund | 1.01% | 0.44% | -0.10 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 23.1%
- Downside volatility
- 22.2%
- Worst 5% of days
- 2.4%
- Average of that tail
- 3.0%
- Max drawdown (1Y)
- 27.3%
- Below its peak
- 21.3%
Against the market
- Beta vs Nifty 50
- 0.47
- Correlation
- 0.27
- Relative strength (3M)
- -18.8%
- ATR (14)
- 3.1%
Return
- Return 1M
- +0.7%
- Return 3M
- -14.9%
- Return 6M
- -6.9%
- Return 1Y
- -6.8%
- vs 200-day average
- -4.9%
Momentum
- RSI (14)
- 48.0
- MACD histogram
- 8.81
- Stochastic %K
- 64.4
- ADX (14)
- 22.4
- +DI / −DI
- 15.5 / 17.3
- Money flow index
- 65.3
Participation
- Delivery (20d avg)
- 54.3%
- vs its 60-day baseline
- -0.7 pts
- Volume vs 20-day
- -0.7σ
- Close vs day's VWAP
- -0.3%
- 52-week position
- 31 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- ₹203 Cr
- FCF yield
- 1.6%
- Cash conversion
- 1.49
- Accruals ratio
- -0.050
- Net debt
- ₹936 Cr
- Net debt / equity
- 0.55
- EV / sales
- 7.10
- PEG
- 3.99
- Capex intensity
- 12.7%
- Revenue CAGR
- 29.9%
- Profit CAGR
- 30.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹3.50
Dividend - Rs 3.50 Per Share
21 Jul 2026ex-date - dividend₹3.00
Dividend - Rs 3 Per Share
27 Jun 2025ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
23 Jul 2024ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
22 Jun 2023ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2 Per Share
7 Sept 2022ex-date
Company announcements
Intimation of execution of lease agreement with APCRDA.
Credit Rating
Initimation for trading window closure for quarter and half year ended September 30, 2026
Outcome of Board Meeting for Appointment of Mr. Sudarshan Patodia as the Chief Financial Officer (KMP) of the Company and other general matters
Intimation of contact details of Key Managerial Personnel authorised under Regulation 30(5) of SEBI (LODR) Regulations, 2015
Intimation for grant of options
Appointment of Mr. Sudarshan Patodia as the Chief Financial Officer (KMP) of the Company
Update on Commencement of Operations at Guntur, Andhra Pradesh.
Intimation of Schedule of Analyst/Institutional Investor Group Meetings.
Resignation of Senior Management Personnel.
Resignation of Mr. Vikas Maheshwari as Chief Financial Officer of the Company w.e.f. August 31, 2026
Update on acquisition
Earnings Call Transcript for the quarter ended June 30, 2026
Link of Audio recording of Earnings Conference call for quarter ended June 30, 2026
Newspaper publication of financial results for quarter ended June 30, 2026
Filed with BSE (scrip 543524); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlides
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 29 Sep from icra
- Rating update · 14 Aug 2025 from icra
- Rating update · 7 Jan 2025 from icra
- Rating update · 6 Dec 2023 from icra
- Rating update · 27 Apr 2023 from icra
- Rating update · 31 Oct 2022 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 1 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Rainbow Childrens Medicare: common questions
Answered from the figures on this page.